title: Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.
abstract: A number of clinical trials have been done to investigate the role of interleukin-6 (IL-6) as a potential therapeutic target in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Most of the data testing this comes from trials of the humanized anti Il-6 receptor antibody tocilizumab. Results from clinical trials worldwide have been promising so far. Additional study will define the ultimate role of tocilizumab and Il6 inhibitors in the treatment paradigms for RA and JIA.
authors: The University of California, San Diego, CA, USA.
authors: Maja
authors: M
authors: Mircic
authors: Arthur
authors: A
authors: Kavanaugh
mesh_terms: D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology; D019947:Receptors, Interleukin-6 / Q000276:immunology; D000093242:Interleukin-6 Inhibitors
chemical_list: D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D000093242:Interleukin-6 Inhibitors